IP will be used to pursue further indications for HT-001 Cancer TherapeuticNEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline.These newly secured patents reflect Hoth's commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on ...

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to attend the Sequire Investor Summit. To learn more about the Sequire Investor Summit, please visit https://puertorico.srax.com/. About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient ...

Financial Position - The company has no plans for a public or private offering at this time [1][3] - The company maintains a strong financial position with over $10 million in cash and no debt [1][3] - This fiscal strength allows the company to execute strategic initiatives and advance its pipeline without immediate need for additional financing [3] Clinical Trials - Enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants [2][4] - HT-001 is the company's lead therapeutic candidate designed to treat rash and skin disorders associated with cancer therapy [4] - Activating all trial sites for HT-001 marks a significant milestone in the development of this promising therapy [5] Company Overview - Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative, patient-focused treatments [2][6] - The company is dedicated to improving patient quality of life through groundbreaking treatments [6] - Hoth collaborates with scientists, clinicians, and key opinion leaders to investigate therapeutics with potential for breakthroughs and diversified treatment options [6] Leadership Statement - The CEO emphasized the company's focus on creating long-term value and advancing clinical programs [4] - The company remains committed to addressing unmet needs for patients undergoing cancer treatment [5] - Hoth is dedicated to transparency and will provide updates as material developments occur [5]

Shares of Hoth Therapeutics (HOTH) skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being developed to address skin toxicities linked to cancer patients undergoing treatment with EGFR inhibitors.Per the data readout from the ongoing phase IIa study, all patients treated with the candidate achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvemen ...

On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors in cancer patients.Data from the open-label portion of the CLEER-001 trial demonstrated:100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.66% of patients reported reduced pain and itching scores, fur ...

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights ...

NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin."As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth. "With recent approval of Bitcoin ETFs and increasing activity from ins ...

Research and Development Expenses - Research and development expenses decreased by $77,000 (7.9%) for the three months ended September 30, 2024 compared to the same period in 2023[134] - Research and development expenses for the three months ended September 30, 2024 were $0.9 million, with $0.6 million allocated to HT-001, $154,300 to HT-KIT, $18,700 to HT-004, and $96,500 to HT-ALZ[135] - Research and development expenses decreased by $635,700 (24.8%) for the nine months ended September 30, 2024 compared to the same period in 2023[141] - Research and development expenses for the nine months ended September 30, 2024 were $1.9 million, with $1.2 million allocated to HT-001, $112,800 to HT-ALZ, $363,300 to HT-KIT, and $96,100 to HT-004[142] General and Administrative Expenses - General and administrative expenses increased by $116,100 (10.4%) for the three months ended September 30, 2024 compared to the same period in 2023[138] - General and administrative expenses increased by $473,500 (13.8%) for the nine months ended September 30, 2024 compared to the same period in 2023[144] Net Loss - Net loss for the three months ended September 30, 2024 was $2.1 million, a decrease of $45,500 compared to the same period in 2023[141] - Net loss for the nine months ended September 30, 2024 was $5.8 million, a decrease of $0.3 million compared to the same period in 2023[150] Cash and Capital Resources - As of September 30, 2024, the company had $8.0 million in cash and cash equivalents and working capital of $7.4 million[151] - The company issued 2,500,000 shares of common stock for net proceeds of $3.8 million during the nine months ended September 30, 2024[152] - Issued new unregistered warrants to purchase up to 3,750,000 shares of common stock at $1.50 per share, expiring on July 3, 2028[154] - Potential milestone payments of up to approximately $10.5 million if all milestones in current agreements are achieved[155] - Net cash used in operations for the nine months ended September 30, 2024, was approximately $5.0 million, primarily due to a net loss of $5.8 million[157] - Net cash provided by financing activities for the nine months ended September 30, 2024, was approximately $3.7 million, resulting from net proceeds from the exercise of warrants[159] - Net cash provided by financing activities for the nine months ended September 30, 2023, was approximately $11.3 million, from the issuance of common stock and warrants[160] Stock-Based Compensation and Valuation - The company estimates the fair value of stock option grants using the Black-Scholes option pricing model, involving inherent uncertainties and management's judgment[164] - Restricted stock awards vest over a service period of zero to three years, with stock-based compensation expense recognized on a straight-line basis[167] - Warrants issued to non-employees vest over a term of zero to ten years, with stock-based compensation expense recognized on a straight-line basis[168] Accounting Standards and Disclosures - The company is evaluating the impact of ASU 2023-09 on income tax disclosures, effective for annual periods beginning after December 15, 2024[171] - The company has a single reportable segment and is evaluating the impact of ASU 2023-07 on segment reporting disclosures, effective for fiscal years beginning after December 15, 2023[175]

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This ...

NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials. HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting ...